A Phase 3 interventional study of Infanrix+Hib™ and Poliorix™ in Acellular Pertussis, Tetanus and Diphtheria, sponsored by GlaxoSmithKline. Completed at 2 sites in China. Open to participants aged 18 Months to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Tetanus by GlaxoSmithKline — none open to participants now, 1 under way, 1 of them phase 3. Tetanus · GlaxoSmithKline.
Among the 106 studies in Tetanus by GlaxoSmithKline, this one is the 15th largest by enrollment of the 98 interventional ones that give a count, is one of 7 that started in 2011, is one of 60 in phase 3, and was the 77th registered.
319 studies on the registry are indexed under Tetanus; 30 are open to participants now.
Browse Tetanus studies →None of the 106 studies in Tetanus by GlaxoSmithKline is open now. The open studies under Tetanus, anywhere →
Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Months to 24 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 831 is above the median of 420 across 281 interventional studies indexed under Tetanus.
Median enrollment 444 across the 98 interventional studies, 664 across the 8 observational. Of the 104 that completed or were terminated, 62 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Tetanus by GlaxoSmithKline that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07596199Phase 3GlaxoSmithKlineA Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women | 2026-11-23 |
Add it to your calendar (.ics) → With an account.
Among the 106 studies in Tetanus by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this booster study is to evaluate the immune persistence in healthy Chinese subjects primed in study NCT01086423 with GSK Biologicals' Infanrix-IPV+Hib™ (DTPa-IPV/Hib) vaccine. The study will also evaluate the safety and immune response of these subjects to a booster dose of Infanrix-Hib™ (DTPa/Hib) and Poliorix™ (IPV) vaccine.
This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT01086423).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
Biological: Infanrix+Hib™ · Biological: Poliorix™
Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
Biological: Infanrix+Hib™ · Biological: Poliorix™
Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
Biological: Infanrix+Hib™ · Biological: Poliorix™
Intramuscular, one dose
Also known as: DTPa /Hib
Intramuscular, one dose
Also known as: IPV
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
Time frame: Before the booster vaccination (At Day 0)
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥0.1 IU/mL.
Time frame: Before the booster vaccination (At Day 0)
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (Anti-PRP)
A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).
Time frame: Before the booster vaccination (At Day 0)
Anti-PRP Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 µg/mL.
Time frame: Before the booster vaccination (At Day 0)
Number of Seroprotected Subjects Against Polio Type 1, 2 and 3
A seroprotected subject was defined as a vaccinated subject with anti-polio type 1, 2 and 3 antibody concentrations ≥ the cut-off value of 8 Estimated Dose 50% (ED50). ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.
Time frame: Before the booster vaccination (At Day 0)
Anti-polio Type 1, 2 and 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ 8.
Time frame: Before the booster vaccination (At Day 0)
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)
A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentration ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/ml).
Time frame: Before the booster vaccination (At Day 0)
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.
Time frame: Before the booster vaccination (At Day 0)
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoids
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.
Time frame: Before the booster vaccination (At Day 0)
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoids
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL.
Time frame: One month after the booster vaccination (At Month 1)
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.1 IU/mL.
Time frame: Before the booster vaccination (At Day 0)
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were presented as GMCs for the seroprotection cut-off of ≥ 0.1 IU/mL.
Time frame: One month after the booster vaccination (At Month 1)
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)
A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentration ≥ 0.15 µg/mL.
Time frame: Before the booster vaccination (At Day 0)
Number of Seroprotected Subjects Against PRP
A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL.
Time frame: One month after the booster vaccination (At Month 1)
Anti-PRP Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 micrograms per milliliter (µg/mL).
Time frame: Before the booster vaccination (At Day 0)
Anti-PRP Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 µg/mL.
Time frame: One month after the booster vaccination (At Month 1)
Number of Seroprotected Subjects for Anti-polio Type 1, 2 and 3
A seroprotected subject was defined as a vaccinated subject with anti-polivirus antibody concentration ≥ 8 ED50. ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.
Time frame: Before the booster vaccination (At Day 0)
Number of Seroprotected Subjects Against Polio Type 1, 2 and 3
A seroprotected subject was defined as a vaccinated subject with anti-polivirus antibody concentrations ≥ 8 ED50. ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.
Time frame: One month after the booster vaccination (At Month 1)
Anti-polio Type 1, 2 and 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ the value of 8.
Time frame: Before the booster vaccination (At Day 0)
Anti-polio Type 1, 2 and 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ 8.
Time frame: One month after the booster vaccination (At Month 1)
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 ELISA units per milliliter (EL.U/mL).
Time frame: Before the booster vaccination (At Day 0)
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
Time frame: One month after the booster vaccination (At Month 1)
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off value of ≥ 5 EL.U/mL.
Time frame: Before the booster vaccination (At Day 0)
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrattions
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.
Time frame: One month after the booster vaccination (At Month 1)
Number of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN
Booster response was defined as the appearance of antibodies in subjects who were initially seronegative (i.e. with concentrations \< cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e. with concentrations ≥ cut-off value), taking into consideration the decreasing maternal antibodies.
Time frame: One month after the booster vaccination (At Month 1)
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 4-day (Days 0-3) post-vaccination period
Number of Subjects With Any Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature equal to or above 37.1 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade and relationship to vaccination.
Time frame: During the 4-day (Days 0-3) post-vaccination period
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day (Days 0-30) post-vaccination period
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (from Month 0 up to Month 1)
6 subjects did not receive vaccination.
| Milestone | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Started | 272 | 273 | 280 |
| Completed | 270 | 273 | 279 |
| Not completed | 2 | 0 | 1 |
| Withdrew: Migrated/moved from study area | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-D | 241 | 250 | 234 |
| Anti-T | 269 | 271 | 275 |
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥0.1 IU/mL.
| IU/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-D | 0.175 (0.163 to 0.188) | 0.189 (0.176 to 0.202) | 0.154 (0.142 to 0.166) |
| Anti-T | 0.45 (0.423 to 0.478) | 0.509 (0.481 to 0.54) | 0.38 (0.359 to 0.404) |
A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (Anti-PRP) | 226 | 234 | 241 |
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 µg/mL.
| µg/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PRP Antibody Concentrations | 2.275 (1.856 to 2.788) | 2.674 (2.193 to 3.26) | 2.413 (2.006 to 2.904) |
A seroprotected subject was defined as a vaccinated subject with anti-polio type 1, 2 and 3 antibody concentrations ≥ the cut-off value of 8 Estimated Dose 50% (ED50). ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-polio 1 | 259 | 267 | 270 |
| Anti-polio 2 | 248 | 261 | 250 |
| Anti-polio 3 | 254 | 259 | 257 |
Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ 8.
| Titers | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-polio 1 | 72.3 (62.4 to 83.7) | 95.7 (82.5 to 111) | 77.2 (67 to 89) |
| Anti-polio 2 | 57.3 (47 to 70) | 63.6 (53.5 to 75.5) | 42.6 (35.7 to 50.8) |
| Anti-polio 3 | 71.3 (60.1 to 84.7) | 79.9 (66.4 to 96.2) | 60.6 (51.2 to 71.8) |
A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentration ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/ml).
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PT | 260 | 263 | 260 |
| Anti-FHA | 262 | 267 | 262 |
| Anti-PRN | 260 | 265 | 267 |
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.
| EL.U/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PT | 10.3 (9.6 to 11.1) | 12.2 (11.3 to 13.1) | 10.4 (9.6 to 11.2) |
| Anti-FHA | 12.8 (11.9 to 13.7) | 14.3 (13.4 to 15.2) | 12.4 (11.5 to 13.4) |
| Anti-PRN | 9.2 (8.8 to 9.7) | 9.7 (9.2 to 10.1) | 9 (8.5 to 9.5) |
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-D | 235 | 245 | 228 |
| Anti-T | 264 | 266 | 268 |
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-D | 265 | 268 | 270 |
| Anti-T | 266 | 268 | 272 |
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.1 IU/mL.
| IU/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-D | 0.174 (0.162 to 0.187) | 0.189 (0.176 to 0.202) | 0.154 (0.142 to 0.166) |
| Anti-T | 0.455 (0.429 to 0.483) | 0.511 (0.482 to 0.542) | 0.38 (0.357 to 0.403) |
Antibody concentrations were presented as GMCs for the seroprotection cut-off of ≥ 0.1 IU/mL.
| IU/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-D | 1.341 (1.239 to 1.451) | 1.504 (1.377 to 1.643) | 1.227 (1.134 to 1.326) |
| Anti-T | 4.862 (4.614 to 5.124) | 4.927 (4.693 to 5.173) | 4.371 (4.161 to 4.591) |
A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentration ≥ 0.15 µg/mL.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) | 221 | 229 | 234 |
A seroprotected subject was defined as a vaccinated subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Number of Seroprotected Subjects Against PRP | 264 | 268 | 271 |
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 micrograms per milliliter (µg/mL).
| µg/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PRP Antibody Concentrations | 2.308 (1.878 to 2.836) | 2.743 (2.245 to 3.352) | 2.407 (1.993 to 2.908) |
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seroprotection cut-off of ≥ 0.15 µg/mL.
| µg/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PRP Antibody Concentrations | 35.178 (30.617 to 40.418) | 49.023 (43.649 to 55.058) | 27.682 (24.251 to 31.598) |
A seroprotected subject was defined as a vaccinated subject with anti-polivirus antibody concentration ≥ 8 ED50. ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-Polio 1 | 253 | 262 | 263 |
| Anti-Polio 2 | 243 | 256 | 244 |
| Anti-Polio 3 | 249 | 254 | 250 |
A seroprotected subject was defined as a vaccinated subject with anti-polivirus antibody concentrations ≥ 8 ED50. ED50 is the estimated serum dilution reducing the signal generated by viral infection with 50%.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-Polio 1 | 265 | 268 | 273 |
| Anti-Polio 2 | 265 | 268 | 273 |
| Anti-Polio 3 | 265 | 268 | 273 |
Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ the value of 8.
| Titers | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-Polio 1 | 72 (62 to 83.7) | 96.3 (82.8 to 112) | 75.9 (65.7 to 87.6) |
| Anti-Polio 2 | 56.5 (46.2 to 69) | 64.1 (53.8 to 76.4) | 41.9 (35 to 50) |
| Anti-Polio 3 | 72.6 (61.1 to 86.3) | 79.4 (65.8 to 95.8) | 60.3 (50.8 to 71.6) |
Antibody titers were presented as geometric mean titers (GMTs) for the seroprotection cut-off of ≥ 8.
| Titers | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-Polio 1 | 3512.2 (3159.7 to 3904.1) | 3410.9 (3081.7 to 3775.4) | 3386.8 (3078 to 3726.6) |
| Anti-Polio 2 | 1931.2 (1721.7 to 2166.2) | 2237.9 (2001.6 to 2502.1) | 1886.1 (1679.6 to 2117.9) |
| Anti-Polio 3 | 5237.8 (4671.8 to 5872.3) | 5438.5 (4846.8 to 6102.4) | 5141.2 (4650.1 to 5684.2) |
A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 ELISA units per milliliter (EL.U/mL).
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PT | 254 | 258 | 253 |
| Anti-FHA | 256 | 262 | 255 |
| Anti-PRN | 254 | 260 | 260 |
A seropositive subject was defined as a vaccinated subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PT | 266 | 268 | 273 |
| Anti-FHA | 266 | 268 | 273 |
| Anti-PRN | 266 | 268 | 273 |
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off value of ≥ 5 EL.U/mL.
| EL.U/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PT | 10.3 (9.5 to 11.1) | 12.2 (11.3 to 13.1) | 10.3 (9.5 to 11.2) |
| Anti-FHA | 12.7 (11.8 to 13.6) | 14.3 (13.4 to 15.2) | 12.3 (11.4 to 13.3) |
| Anti-PRN | 9.2 (8.7 to 9.6) | 9.7 (9.2 to 10.2) | 9 (8.5 to 9.5) |
Antibody concentrations were presented as geometric mean concentrations (GMCs) for the seropositivity cut-off of ≥ 5 EL.U/mL.
| EL.U/mL | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PT | 138.5 (132 to 145.3) | 146.2 (139.7 to 153) | 126.8 (120.4 to 133.5) |
| Anti-FHA | 124.6 (119.2 to 130.2) | 124 (119.2 to 129) | 120.8 (115.3 to 126.6) |
| Anti-PRN | 57.3 (55.6 to 59.1) | 59.9 (58.1 to 61.8) | 57.2 (55.3 to 59.1) |
Booster response was defined as the appearance of antibodies in subjects who were initially seronegative (i.e. with concentrations \< cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e. with concentrations ≥ cut-off value), taking into consideration the decreasing maternal antibodies.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Anti-PT | 266 | 268 | 272 |
| Anti-FHA | 266 | 268 | 272 |
| Anti-PRN | 239 | 230 | 244 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Any Pain | 73 | 74 | 76 |
| Any Redness | 19 | 15 | 19 |
| Any Swelling | 16 | 10 | 14 |
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature equal to or above 37.1 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade and relationship to vaccination.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Any Drowsiness | 38 | 50 | 38 |
| Any Irritability | 78 | 81 | 72 |
| Any Loss of appetite | 67 | 73 | 69 |
| Any Fever | 102 | 105 | 91 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | 16 | 13 | 21 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 1 | 0 | 0 |
Collected over Solicited local and general symptoms: during the 4-day (Days 0-3) post-vaccination period. AEs: within the 31-day (Days 0-30) period following booster vaccination. SAEs: throughout the entire study period (from Month 0 up to Month 1).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infanrix+Hib/Poliorix 1 Group | 0/272 (0%) | 1/272 (0.4%) | 157/272 (57.7%) |
| Infanrix+Hib/Poliorix 2 Group | 0/273 (0%) | 0/273 (0%) | 164/273 (60.1%) |
| Control Group | 0/280 (0%) | 0/280 (0%) | 158/280 (56.4%) |
| Event | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| Febrile convulsionNervous system disorders | 1/272 | 0/273 | 0/280 |
| BronchopneumoniaInfections and infestations | 1/272 | 0/273 | 0/280 |
| Event | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group |
|---|---|---|---|
| FeverGeneral disorders | 102/270 | 105/273 | 91/279 |
| IrritabilityGeneral disorders | 78/270 | 81/273 | 72/279 |
| PainGeneral disorders | 73/270 | 74/273 | 76/279 |
| Loss of appetiteGeneral disorders | 67/270 | 73/273 | 69/279 |
| DrowsinessGeneral disorders | 38/270 | 50/273 | 38/279 |
| RednessGeneral disorders | 19/270 | 15/273 | 16/279 |
| SwellingGeneral disorders | 16/270 | 10/273 | 14/279 |
| Age, Continuous(Months) | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group | Total |
|---|---|---|---|---|
| Mean | 19.5 ± 0.93 | 19.4 ± 0.91 | 19.5 ± 0.97 | 19.47 ± 0.94 |
| Sex: Female, Male(Participants) | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group | Total |
|---|---|---|---|---|
| Female | 131 | 126 | 120 | 377 |
| Male | 141 | 147 | 160 | 448 |
| Race/Ethnicity, Customized(Participants) | Infanrix+Hib/Poliorix 1 Group | Infanrix+Hib/Poliorix 2 Group | Control Group | Total |
|---|---|---|---|---|
| Asian-Chinese heritage | 272 | 273 | 280 | 825 |
The record gives a start of Oct 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 5 years 2 months after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poliovirus Vaccine, Inactivated